Substituted Oxadiazole 2-Oxides as a Treatment of Schistosomiasis
Lead Inventor: Craig Thomas (NCATS)
Inventors: Ganesha Bantukallu (NCATS), David Maloney (NCATS), Ahmed Sayed (Illinois State University), Anton Simeonov (NCATS), David Williams (Illinois State University)
Ref. No.: E-162-2008/0
Abstract: Available for licensing and commercial development are pharmaceutical compositions and methods for the treatment of schistosomiasis in mammals. The various compositions are based on a number of compounds derived from 1,2,5-oxadiazole that are potent inhibitors of thioredoxin glutathione reductase (TGR), a critical parasite redox protein.
Structure Mechanism Insights and the Role of Nitric Oxide Donation Guide the Development of Oxadiazole-2-Oxides as Therapeutic Agents against Schistosomiasis • Journal of Medicinal Chemistry • October 2009 • NCATS Chemical Genomics Center
Identification of Oxadiazoles as New Drug Leads for the Control of Schistosomiasis • Nature Medicine • April 2008 • NCATS Chemical Genomics Center